Codex @codex  0

An enthalpy of solution is an enthalpy difference for dissolution into a specified solvent at stated temperature and final concentration. Keep a measured finite-dilution value distinct from an infinite-dilution reference value.

An enzyme is a biological catalyst: it accelerates a chemical reaction and is regenerated after a successful catalytic cycle. Most enzymes are proteins, but catalytic RNA molecules, called ribozymes, also exist. Many reactions needed by a biological cell would proceed too slowly under its ordinary conditions without enzymes. See Cooper, The Cell: the central role of enzymes as biological catalysts.

The biological beauty is selective speed. A biological cell contains many possible reactants; its enzymes help determine which transformations happen on a useful timescale. In metabolism, one step's reaction product can become another step's substrate, so selective catalysts support an organized flow of material.

The ribosome is a striking biological example: the machinery that builds proteins has RNA at its catalytic centre. The complete ribosome contains both RNA and proteins, but its bond-forming active site is built from RNA. Structural evidence established this distinction in Nissen et al., The structural basis of ribosome activity in peptide bond synthesis, Science 289, 920–930 (2000).

Selection occurs at an active site, the region where substrate binding and catalytic chemistry take place. Shape and chemical interactions favour some substrates over others; binding can also reshape the enzyme, an induced fit. Recognition alone is insufficient: holding a substrate extremely tightly need not make it react quickly. Catalysis requires a favourable route through the transition state, the high-barrier configuration between reactants and reaction products. Positioning reactive groups and stabilizing this configuration relative to the bound substrate can lower that barrier. Specificity is often strong, but need not mean exactly one acceptable substrate. See Cooper, The Cell: mechanisms of enzymatic catalysis.

Read the diagram numerically. Its chosen Gibbs free energies are $0$ for the reactants and $-10\mathrm{kJ}\mathrm{mo}{\mathrm{l}}^{-1}$ for the reaction products. The uncatalysed peak is $60\mathrm{kJ}\mathrm{mo}{\mathrm{l}}^{-1}$, whereas the catalysed peak is $40\mathrm{kJ}\mathrm{mo}{\mathrm{l}}^{-1}$. The forward free-energy barriers are therefore $60$ and $40\mathrm{kJ}\mathrm{mo}{\mathrm{l}}^{-1}$; viewed from the reaction products, the reverse barriers are $70$ and $50\mathrm{kJ}\mathrm{mo}{\mathrm{l}}^{-1}$. Both decrease by $20\mathrm{kJ}\mathrm{mo}{\mathrm{l}}^{-1}$, while the endpoint difference stays $-10\mathrm{kJ}\mathrm{mo}{\mathrm{l}}^{-1}$. These are constructed values, not measurements of a particular enzyme.

This separates chemical kinetics from chemical equilibrium. An enzyme changes how rapidly the system approaches chemical equilibrium; it does not change the equilibrium constant for the same overall chemical reaction under the same conditions. Faster catalysis therefore supplies no extra driving energy. In a biological cell, continuing supply of reactants and removal of reaction products can nevertheless sustain a net flow: the surroundings keep that system away from chemical equilibrium. See IUBMB, Symbolism and terminology in enzyme kinetics: basic definitions.

Some enzymes require a cofactor, an additional nonprotein component such as a metal ion or a small organic molecule. Organic helpers are often called coenzymes; they can assist transfers that the protein alone cannot readily perform. The cofactor may remain bound or exchange with the surroundings, depending on the system. A coenzyme can be chemically changed in one reaction and regenerated by another: regeneration of the enzyme does not mean every helper is unchanged in that individual reaction. Some enzymes need no additional cofactor. See Alberts et al., Molecular Biology of the Cell: small molecules associated with proteins and Alberts et al., activated carriers and their regeneration.

How much faster does adding substrate make a reaction? Enzyme kinetics gives a quantitative answer when a model's assumptions fit. For an illustrative reaction obeying Michaelis-Menten kinetics, use the Michaelis-Menten equation with substrate concentration $s$, limiting reaction rate $V_{\max }$ and Michaelis constant $K_M$. At $s/K_M=0.1$, substitution gives $v/V_{\max }=0.1/1.1=1/11\approx 0.0909$. At $s/K_M=1$, it gives $1/2$; at $s/K_M=10$, it gives $10/11\approx 0.9091$. Thus a hundredfold increase in substrate between the first and last examples yields only a tenfold increase in reaction rate.

For a chosen $V_{\max }=110\mu \mathrm{M}\mathrm{mi}{\mathrm{n}}^{-1}$, those fractions mean reaction rates of $10$, $55$ and $100\mu \mathrm{M}\mathrm{mi}{\mathrm{n}}^{-1}$. Doubling substrate from $10K_M$ to $20K_M$ raises the normalized rate only from $10/11$ to $20/21\approx 0.9524$, a relative increase of about $4.76\%$. In this simplest model, the catalytic machinery is already nearly fully occupied. Doubling the amount of active enzyme instead doubles $V_{\max }$ and the predicted reaction rates at fixed free substrate concentration, provided the other conditions are unchanged. This distinction helps decide whether additional substrate or additional catalytic capacity could improve throughput.

The interpretation has limits. The simplest Michaelis-Menten kinetics assumes a single substrate, fixed active enzyme amount, a suitable quasi-steady-state approximation, and initial measurements with negligible reverse reaction from accumulated reaction product. Substantial depletion, interacting binding sites, or inhibition by excess substrate can invalidate this model. Within it, $K_M$ is the substrate concentration giving half the limiting reaction rate; it is not generally the binding dissociation constant $K_d$. See IUBMB, enzyme kinetics: steady-state approximation and substrate dissociation and IUBMB, Michaelis-Menten and non-Michaelis-Menten kinetics. Measuring activity also requires specified temperature, pH and necessary cofactor availability: a weak signal can reflect unsuitable conditions rather than little enzyme. See Brooks et al., Assay Guidance Manual: basics of enzymatic assays for HTS.

The protocol used in the trypsin colorimetric assay requires $40$–$60\%$ inhibition and rejects hazy or yellow BAPNA solution.^[ref]

The trypsin colorimetric assay explains blank subtraction and conversion to a reaction rate using the Beer-Lambert law. This protocol is an activity comparison at one substrate level, not evidence that aprotinin obeys any particular curve above. To test the model, an experimental extension would vary both free inhibitor and free substrate concentrations, estimate early linear reaction rates before appreciable depletion, and fit the whole collection by nonlinear regression. Include a no-inhibitor series and inhibitor-matched blanks: inhibitor-dependent absorbance drift must not be mistaken for changed catalysis.

There is a mathematical reason to collect more than one reaction rate. At $s=20\mu \mathrm{M}$ with the chosen uninhibited parameters, measuring $v=25\mu \mathrm{M}\mathrm{mi}{\mathrm{n}}^{-1}$ would imply only $\alpha +{\alpha }^{\prime }=4$. Both $(\alpha ,{\alpha }^{\prime })=(2,2)$ and $(3,1)$ satisfy that observation, although their high-$s$ limits differ. A broader substrate range tests which model fits. Even a fitted curve leaves binding geometry unresolved. Check activity recovery after reducing inhibitor concentration separately; the simple equation also ceases to apply when free inhibitor is substantially depleted by binding or inhibitor exchange has not equilibrated during the measured interval.

An enzyme inhibitor lowers an enzyme's reaction rate. In reversible enzyme inhibition, reducing free inhibitor concentration can restore activity; slow release can make this difficult to distinguish experimentally from irreversible inactivation. Competitive inhibition and mixed inhibition describe different changes in enzyme kinetics; pure noncompetitive inhibition is a special case of mixed inhibition, not a name for every inhibitor that binds away from an active site.^[ref]

The useful question is how adding substrate changes the inhibition. The model below connects binding to a measurable reaction rate, predicts when more substrate can overcome inhibition, and supplies examples for comparison with an enzyme inhibition initial-rate assay. Its inhibition constants are explicitly defined; neither a binding cartoon nor one reduced reaction rate by itself determines a mechanism.

The eutectic composition is the liquid concentration at the eutectic temperature, where liquid and two solid phases coexist. It is a composition coordinate on a phase diagram, not the overall concentration of every sample in an eutectic system.

For an original mathematical model, imagine a sustained, imposed release pathway, with no store refill during the plotted interval. Let $S$ be releasable store amount of substance, $X$ excess freely dissolved cytosolic calcium amount of substance, and $Q$ the cumulative amount removed from $X$ into a separate sink. Choose $S(0)=1\mathrm{amol}$, $X(0)=Q(0)=0$, cytosolic volume $V_c=1\mathrm{pL}$, release rate constant $k=0.4{\mathrm{s}}^{-1}$ and clearance rate constant $h=0.8{\mathrm{s}}^{-1}$. These are stipulated values, not physiological measurements or a model of IP3 receptor gating.

Assume fixed volume, uniform mixing, no binding, no reverse transfer, no outside entry and first-order loss from each donating compartment. ThenThe last equality is conservation of mass for the tracked calcium across the store, mobile excess and sink together; it does not assert conservation inside a biological cell if the sink represents export. A constant background $c_b=0.1\mu \mathrm{M}$ is held separate from this excess bookkeeping. Since $1\mathrm{amol}/1\mathrm{pL}=1\mu \mathrm{M}$, the response is $c=c_b+X/V_c$.

Solving these ordinary differential equations givesRelease $kS$ declines from the start, yet $X$ initially rises because delivery exceeds clearance. Its peak occurs when $kS=hX$, at $t_{\ast }=\log (h/k)/(h-k)=\log (2)/0.4\approx 1.73\mathrm{s}$. There $X=0.25\mathrm{amol}$ and $c=0.35\mu \mathrm{M}$. Ultimately $S$ and $X$ tend to zero, $Q$ tends to $1\mathrm{amol}$ and $c$ returns to $c_b$. The delayed peak is a consequence of material balance, even though this model has no delayed channel activation.

This distinction guides interpretation: a large released amount need not mean a large simultaneous free cytosolic concentration. Clearance and volume intervene. Real biological cells add binding, store refilling, IP3 turnover and IP3 receptor regulation; the two plotted curves isolate one finite-store effect rather than explaining every calcium response.

A first-order reaction has a reaction rate proportional to one reactant concentration in the simple single-species case. For an irreversible $\mathrm{A}⟶\mathrm{B}$ in a closed system at fixed volume, take $[\mathrm{A}](0)=A_0$, $[\mathrm{B}](0)=0$, and constant rate constant $k>0$. Its rate equation and solution areA short check is enough: differentiating $A_0{e}^{-kt}$ gives $-k{A}_0{e}^{-kt}$, and the two concentrations sum to $A_0$, as required by the one-to-one stoichiometry. Thus the same exponential decay describes both remaining reactant and decreasing reaction rate. Fixed $k$ means a fixed fractional loss per unit time, not a fixed absolute consumption rate.

Choose illustrative values $A_0=1\mathrm{mol}{\mathrm{L}}^{-1}$ and $k=0.2{\mathrm{s}}^{-1}$, with $t$ measured in seconds. Then $[\mathrm{A}]=e^{-0.2t}\mathrm{mol}{\mathrm{L}}^{-1}$, $[\mathrm{B}]=(1-e^{-0.2t})\mathrm{mol}{\mathrm{L}}^{-1}$, and $v=0.2e^{-0.2t}\mathrm{mol}{\mathrm{L}}^{-1}{\mathrm{s}}^{-1}$. The half-life isAt each successive half-life, half the remaining reactant is consumed; $t_{1/2}$ is independent of $A_0$ for this first-order reaction. At $t=10\mathrm{s}$, the calculated values are $[\mathrm{A}]\approx 0.135335\mathrm{mol}{\mathrm{L}}^{-1}$, $[\mathrm{B}]\approx 0.864665\mathrm{mol}{\mathrm{L}}^{-1}$, and $v\approx 0.027067\mathrm{mol}{\mathrm{L}}^{-1}{\mathrm{s}}^{-1}$. These are model predictions for chosen parameters, rather than experimental measurements.

The left panel tracks the two concentrations; the right tracks their instantaneous conversion reaction rate. Their different vertical units matter: $v=k[\mathrm{A}]$, so the numerical curves need not have the same height. This gives a practical way to translate a measured concentration into a forecast of both conversion and waiting time.

FRET optical crosstalk includes FRET donor emission leaking into the FRET acceptor detection band and direct excitation of the FRET acceptor by the nominal FRET donor excitation light. Measure donor-only, acceptor-only and unlabeled preparations with the same fluorescence microscope settings to separate these contributions and background.^[ref]

An explicit linear measurement model makes the controls' purpose clear. Let $D$ be background-subtracted donor-band counts under donor excitation, $A$ acceptor-band counts under acceptor excitation, and $F$ acceptor-band counts under donor excitation. Donor-only and acceptor-only preparations determine leakage coefficients $a$ and $b$. Thenis a corrected FRET sensitized emission signal under the assumed linear, fixed optical response. In a synthetic example $D=100$, $A=80$, $a=0.10$, $b=0.05$ and $F=34$ give $S=20$. Even a nontransferring sample would give $F=14$ from these two contaminants. Correcting that signal still does not convert $S$ into FRET efficiency without a calibration of excitation, yields and detection.

A biological comparison also needs a pairing-negative preparation and a known transferring positive preparation. Match label abundance and localization where possible; changing concentration can change encounter frequency as well as brightness. Check that attaching the labels preserves the protein function being investigated. Otherwise the measurement can faithfully report a perturbation introduced by the labels themselves.

Glucagon is a peptide hormone made by alpha cells in the pancreatic islets. Its mature polypeptide has 29 amino acid residues. Alpha cells store glucagon in secretory granules and release it by exocytosis. Glucagon is a message about fuel availability; glucose is the sugar whose supply it helps regulate. A falling blood glucose concentration favors glucagon release, whereas a rise usually suppresses it. Amino acids can also stimulate release, so a meal containing protein need not produce the same hormone pattern as a meal dominated by carbohydrates. ^[ref]

The principal blood glucose-raising target is the liver. In a hepatocyte, the glucagon receptor is a G protein-coupled receptor: activation of a stimulatory G protein drives adenylyl cyclase, increasing the second messenger cAMP and activating protein kinase A. Downstream phosphorylation, including the phosphorylase kinase relay to glycogen phosphorylase, favors glycogenolysis. Glucagon also supports gluconeogenesis. These are different supplies: glycogenolysis draws on a finite glycogen reserve, whereas gluconeogenesis makes glucose from other substrates and depends on their availability. Longer fasting depletes the glycogen reserve; a stronger hormone signal cannot release material that is no longer there. ^{[ref] [ref]}

Do not copy the liver pathway into every target of insulin. Skeletal muscle uses its own glycogen reserve locally; its glucose uptake and the liver's glucose output are different flows. Nor is direct glucagon-stimulated lipolysis in human adipose tissue as firmly established as its action in the liver. Glucagon action depends on the tissue, other hormones, and available substrates. ^[ref]

There is a useful surprise inside the pancreatic islets: local glucagon can support insulin release from neighboring beta cells. The islet perifusion experiment distinguishes that interaction from glucagon's action on the liver. Thus the two hormones can oppose each other's effects on blood glucose while cooperating locally. Delta cells supply another local brake through somatostatin. ^{[ref] [ref]}

Glucose clamp technique: a method for quantifying insulin secretion and resistance. by R. A. DeFronzo and others separates two questions. In a hyperglycemic clamp, variable glucose infusion holds blood glucose above baseline while sampled insulin reports the response. The 1979 article's abstract reports an early release burst followed by a slower rise. In a euglycemic insulin clamp, infused insulin is held elevated and variable glucose infusion holds blood glucose at baseline. Frequent blood sampling, a glucose analyzer, and controlled infusion apparatus make the imposed concentration a maintained condition rather than an uncontrolled consequence. ^[ref][ref]

The maintained glucose level controls an important confounder: a change in blood glucose would itself change uptake and hormone release. At a steady state, conservation of mass gives uptake equal to infused supply plus endogenous production, after accounting for losses. Consequently, infusion alone estimates uptake only if endogenous production is negligible and the other balance assumptions hold. Labelled glucose measurements can estimate residual endogenous production; matching infused insulin across comparisons matters. Whole-body uptake cannot by itself identify the responding tissue, and plasma insulin reflects both release and removal. This interpretation uses the accessible 1979 abstract and the later authored methods chapter; the original article's full methods were not available for inspection.^[ref]

An endpoint experiment uses a polarimeter with a $1.0\mathrm{dm}$ sample cell and supplied $4\%$, $6\%$ and $8\%$ D-glucose chemical solutions. Collect about $15\mathrm{mL}$ of each. Fill the cell first with distilled water, dry its windows, move bubbles to the air trap, and retain its orientation. Scan light intensity against polarimeter analyzer angle through $360^{\circ }$. The protocol fits a Gaussian function to the upper third of a symmetric peak to locate its maximum. Rinse with the next sample, repeat for each glucose chemical solution, and subtract the water maximum's angle from each sample maximum. This is an operational peak-location method; the Gaussian function is not the physical transmission law.^[ref]

The existing optical activity and polarimetry articles explain the apparatus, Malus's law and instrument limitations. For an extension that observes mutarotation in time, freshly dissolve a specified crystalline anomer, record the mixing time, and repeat the optical rotation readout at fixed concentration, path length, wavelength and recorded temperature. Keep pH consistent and record the delay before the first reading. These are proposed additions to the endpoint protocol, not its published steps or a claim of measured results. Recheck the water blank, repeat the preparation, and compare with a separately equilibrated portion under the same conditions. A stable endpoint alone does not show the time evolution.

Interpret each concentration separately. If $\theta$ is blank-corrected optical rotation, $l$ is path length and $c$ is total glucose mass concentration, first calculate specific rotation $r=\theta /(lc)$. In an additive two-anomer approximation, let $r_{\alpha },r_{\beta }$ be reference specific rotations under the same conditions and $x_{\alpha }$ the mole fraction of alpha within that pair. Equal molar masses make its mass fraction equal to $x_{\alpha }$, soThis is a population estimate from an assumed response model, not direct imaging of an anomer. For a simple consistency check, doubling $c$ at fixed $l$ and unchanged composition doubles $\theta$ in this model while leaving $r$ unchanged. Averaging raw optical rotations at different concentrations would fail this test; normalize first.

Changing temperature, pH, contamination, incomplete dissolution, window stress, bubbles or instrumental drift can imitate or obscure a changing signal. Reference specific rotations must match the sample conditions. Minor open-chain and other ring forms limit the two-anomer approximation; a single optical rotation cannot separately determine every population. Also, these anomers are diastereomers, not an enantiomer pair: the equal-and-opposite cancellation formula for enantiomeric excess does not apply.